Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma
Status:
Recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
Every year, about 6% of patients with malignant tumors are diagnosed as head and neck cancer.
There are about 650000 new cases and 350000 deaths. A considerable number of patients have
simple local recurrence in the short term after operation suggesting that the biological
behavior of this kind of tumor is relatively more invasive and the overall prognosis is poor.
This project intends to study the efficacy and safety of camrelizumab combined with
concurrent chemoradiotherapy for short-term postoperative progression of head and neck
squamous cell carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences